Peak HumanDatabase
    All Research
    PAPER GFAP-PCohort Study

    Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease

    Plasma GFAP outperformed CSF GFAP for detecting amyloid pathology and was associated with clinical progression in early Alzheimer's disease.

    Evidence

    6/10

    Moderate Evidence

    Sample

    —

    subjects

    Duration

    —

    study period

    Journal

    —

    02

    Key Findings

    1. 01

      Plasma GFAP outperformed CSF GFAP for amyloid detection

    2. 02

      Higher plasma GFAP associated with clinical progression in early AD

    03

    Structured Methods

    Study Design
    Cohort Study
    Sample Size
    Not reported
    Study Duration
    Not reported
    Methodology
    Not reported
    Limitations
    Not reported
    04

    Citations & References

    Cite this paper

    Unknown authors (n.d.). Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.

    Source

    Publisher

    05

    Indexing

    Topics

    Alzheimer'samyloid

    Biomarkers

    GFAP
    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation
    See your Peak Human Score How it works